Find the epitope specificity of your T-cell receptors with
machine learning
Find and track the T cells that matter
Accelerate the development of your therapeutics and diagnostics by truly understanding T-cell responses. ImmuneWatch’s machine learning platform can annotate the epitope specificity of T-cell receptor (TCR) sequences, turning TCR repertoires into clinically actionable data.
ImmuneWatch DETECT
Extract therapy-, vaccine- or pathogen-specific TCRs from TCR repertoires to fully understand T-cell responses. Run ImmuneWatch’s machine learning platform on your own infrastructure or work with us to get the insights you need.
ImmuneWatch DESIGN
Find the right T cell epitopes and antigens for your vaccine with ImmuneWatch’s reverse vaccinology pipeline. Start from a protein or genome and get a ranked list of immunogenic epitopes or antigens.
How our technology works
TCR sequencing
TCR sequencing offers you an unprecedented deep insight in the composition of the T-cell receptor repertoire of a patient and its dynamics in response to a T-cell therapeutic or vaccine.
TCR sequencing can be performed on PBMCs, stimulated cells or tissue samples. ImmuneWatch’s technology is compatible with single cell or -bulk sequencing approaches.
Annotate the epitope specificity of TCRs
A bottle-neck in the analysis of TCR repertoires is the annotation of the epitope-specificity of TCRs. Based on > 7 years of research, ImmuneWatch has developed explainable machine learning algorithms (IMW-DETECT) that can link TCRs to their cognate epitope sequences. Find your therapy-, vaccine- or pathogen-specific TCRs in less than 2 minutes.
Immunoinformatic pipelines
ImmuneWatch is dedicated to offer a complete solution, from sequencing to immunoinformatics analysis. As experts in immunology and bioinformatics ImmuneWatch is able to provide a complete immunoinformatic pipeline from FASTQ to interactive reports.
Reverse vaccinology pipeline
Predict what parts of a pathogen will be most effective in a vaccine. ImmuneWatch’s unique algorithms provide not only insights in epitope presentation, but also into the prevalence of T cells that can potentially bind the peptide-MHC complexes (patent pending).
Together with ImmuneWatch we were able to assess vaccine-induced T-cell signatures in our unique longitudinal sample collection of cancer patients. Based on antibody titers, it has previously been shown that cancer patients induce a weaker response towards COVID19 vaccines. T-cell immunity in this context is far less characterized and understood. Thanks to the ImmuneWatch DETECT platform we were able to take a deep dive into the SARS-CoV-2-specific T-cell response of our cancer patient cohort.
ImmuneWatch assisted us in analysing reactive T-cells through TCR sequencing and data anaysis in an oncology setting. Together, we identified potential TCR candidates for further in vitro validation. This collaboration provided us with insights into T-cell reactivity and the immune profile of our stimulation experiments, advancing our understanding and guiding future research.
The DESIGN analysis performed by ImmuneWatch is very informative and useful for making decisions on our different candidate antigens. Thank you for this nice work!
Some of our latest insights
Find the epitope-specificity of your TCRs today
